Register / Login

We're evolving!

The website is currently being upgraded to include our new suite of offerings. Check back at the end of the month for a breakdown of our new services!

Questions? Contact us at:

office@md-education.com

3rd Annual

CAR-T & Bispecifics

US Focus Meeting

Updating Knowledge & Clinical Practice in 2025

Kimpton Marlowe Hotel, Massachusetts

Friday 7 March 2025 - Saturday 8 March 2025

Presentations will be available online for 12 months

Meeting content distributed to 12,000+ HCPs

For more information get in touch!

=

Co-chair

Nitin Jain, MD

MD Anderson Cancer Center, Houston, Texas

=

Co-chair

Noopur Raje, MD

Massachusetts General Hospital, Boston, Massachusetts

=

Co-chair

Sattva Neelapu, MD

MD Anderson Cancer Center, Houston, Texas

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the multinational congress CAR-T & Bispecifics US Focus 2025, to be held at Kimpton Marlowe Hotel, Massachusetts on 7 March 2025.

This meeting provides pivotal collaboration aimed at advancing CAR-T & Bispecifics research and patient treatment.

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts from around the world.

Engage in riveting presentations, participate in thought-provoking debates, round-table discussions, and connect with peers at informal social gatherings.

All meeting content will be accessible online for a full year, reaching an extensive audience of healthcare professionals worldwide.

People stood in a circle, smiling, with a cup of water

Agenda & Faculty

CAR-T & Bispecifics US Focus Meeting, Friday 7 March 2025 - Saturday 8 March 2025

08:00

Registration Opens

08:50

Opening Remarks – Ryan Fitzpatrick, CEO, MD Education

09:00

Mechanisms of Resistance to CAR-T Cell Therapy

=

Marco Ruella, MD

University of Pennsylvania, Pennsylvania

Session 1: Myeloma Part I

09:30

Sequencing of Bispecifics and CAR-T Cells

=

Adam D Cohen, MD

University of Pennsylvania, Pennsylvania

09:50

Moving Bispecifics and CAR-T Cells Early in Myeloma

=

Adam Sperling, MD

Dana-Farber Cancer Institute, Boston, Massachusetts

10:10

Challenges with Access to CAR-T Cells in the Real World

=

Ben Derman, MD

University of Chicago Medical Center, Chicago, Illinois

10:20

Panel Discussion

10:40

Coffee Break

Session 2: Myeloma Part II

11:10

Use of T-Cell Redirected Therapies in Smoldering Multiple Myeloma

=

Irene Ghobrial, MD

Dana-Farber Cancer Institute, Boston, Massachusetts

11:30

Practical Considerations: Long-term Toxicities and Supportive Care with T-Cell Redirected Therapies

=

Krina Patel, MD

MD Anderson Cancer Center, Houston, Texas

11:50

Novel TCRs in Myeloma

=

Sham Mailankody, MD

Memorial Sloan Kettering Cancer Center, New York

12:10

Panel Discussion

12:30

Lunch Break + Faculty and Fellow Photo

13:20

Industry Supported Independent Expert Discussion

Session 3: Lymphoma Part I

14:05

When to Use CAR-T vs Bispecifics in LBCL

=

Paolo Strati, MD

MD Anderson Cancer Center, Houston, Texas

14:25

When to Use CAR-T vs Bispecifics in Follicular Lymphoma

=

Carla Casulo, MD

University of Rochester, New York

14:45

When to Use CAR-T vs Bispecifics in MCL

=

Tycel Phillips, MD

City of Hope, California

15:05

Panel Discussion

15:25

Coffee Break

Session 4: Lymphoma Part II

15:45

Administering CAR-T and Bispecifics in the Outpatient Setting

=

Yi Lin, MD

Mayo Clinic, Minnesota

16:05

Novel Autologous CAR-T Cell Therapies in NHL

=

Matthew Frank, MD

Stanford University, California

16:25

Allogeneic Cell Therapies in NHL

=

Caron Jacobson, MD

Dana-Farber Cancer Institute, Boston, Massachusetts

16:45

Panel Discussion

17:05

Adjourn